Breaking News Instant updates and real-time market news.

2020-10-12 07:32:07 RVMD Revolution Medicines $39.80 / -0.5 (-1.24%) 07:32 10/12/20 10/12 07:32 10/12/20 07:32	Revolution Medicines to present interim fata from Phase 1b/2 trial of RMC-4630 Revolution Medicines announced that interim data from the company's ongoing Phase 1b/2 clinical trial evaluating the combination of RMC-4630 and cobimetinib will be reported in an oral presentation in a plenary session at the upcoming EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics being held virtually October 24-25, 2020. The ongoing Phase 1b/2 RMC-4630-02 trial is an open-label, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic proles of RMC-4630 and cobimetinib in adult patients with relapsed/refractory solid tumors that harbor specific genomic mutations. The study tested several dosing regimens, including intermittent RMC-4630 plus daily or intermittent cobimetinib. Preliminary data to be presented at ENA 2020 will focus on safety, tolerability and pharmacokinetic findings from combination dosing regimens. Details of the upcoming oral presentation at ENA 2020 are as follows: Title: Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a Phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling Session: Plenary Session 1: Late-Breaking and Best Proffered Papers Presenting Author: Johanna C. Bendell, M.D., Sarah Cannon Research Institute, Nashville, Tennessee Presentation Date/Time: Saturday, October 24, 2020, 3:45 - 3:55 p.m. RMC-4630 and cobimetinib are targeted inhibitors of oncogenic proteins at distinct positions within the RAS signaling cascade that is frequently exploited by human cancers and may develop adaptive resistance to single agent treatment. RMC-4630 is a potent and orally bioavailable small molecule designed to selectively inhibit the activity of SHP2, an upstream cellular protein that plays a key role in modulating cell growth by transmitting signals from receptor tyrosine kinases to RAS. Cobimetinib, marketed in the U.S. by Genentech, a member of the Roche group, inhibits the activity of MEK, a downstream effector of RAS that affects cell survival and growth. Cobimetinib is approved in the U.S. for the treatment of patients with BRAFV600E or BRAFV600K mutation-positive unresectable or metastatic melanoma in combination with vemurafenib.	13 Feb 09 Jul
RVMD Revolution Medicines $39.80 / -0.5 (-1.24%) 09/14/20 Jefferies Inhibrx initiated with a Buy at Jefferies 05/21/20 Fly Intel: Top five analyst initiations 05/21/20 H.C. Wainwright Revolution Medicines initiated with a Buy at H.C. Wainwright 03/09/20 Fly Intel: Top five analyst initiations

2020-10-12 07:32:07

RVMD

Revolution Medicines

$39.80 / -0.5 (-1.24%)

07:32

10/12/20

10/12

07:32

10/12/20

07:32

Revolution Medicines to present interim fata from Phase 1b/2 trial of RMC-4630

Revolution Medicines announced that interim data from the company's ongoing Phase 1b/2 clinical trial evaluating the combination of RMC-4630 and cobimetinib will be reported in an oral presentation in a plenary session at the upcoming EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics being held virtually October 24-25, 2020. The ongoing Phase 1b/2 RMC-4630-02 trial is an open-label, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic proles of RMC-4630 and cobimetinib in adult patients with relapsed/refractory solid tumors that harbor specific genomic mutations. The study tested several dosing regimens, including intermittent RMC-4630 plus daily or intermittent cobimetinib. Preliminary data to be presented at ENA 2020 will focus on safety, tolerability and pharmacokinetic findings from combination dosing regimens. Details of the upcoming oral presentation at ENA 2020 are as follows: Title: Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a Phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling Session: Plenary Session 1: Late-Breaking and Best Proffered Papers Presenting Author: Johanna C. Bendell, M.D., Sarah Cannon Research Institute, Nashville, Tennessee Presentation Date/Time: Saturday, October 24, 2020, 3:45 - 3:55 p.m. RMC-4630 and cobimetinib are targeted inhibitors of oncogenic proteins at distinct positions within the RAS signaling cascade that is frequently exploited by human cancers and may develop adaptive resistance to single agent treatment. RMC-4630 is a potent and orally bioavailable small molecule designed to selectively inhibit the activity of SHP2, an upstream cellular protein that plays a key role in modulating cell growth by transmitting signals from receptor tyrosine kinases to RAS. Cobimetinib, marketed in the U.S. by Genentech, a member of the Roche group, inhibits the activity of MEK, a downstream effector of RAS that affects cell survival and growth. Cobimetinib is approved in the U.S. for the treatment of patients with BRAFV600E or BRAFV600K mutation-positive unresectable or metastatic melanoma in combination with vemurafenib.

13
Feb
09
Jul

RVMD Revolution Medicines

$39.80 / -0.5 (-1.24%)

09/14/20 Jefferies: Inhibrx initiated with a Buy at Jefferies

05/21/20: Fly Intel: Top five analyst initiations

05/21/20 H.C. Wainwright: Revolution Medicines initiated with a Buy at H.C. Wainwright

03/09/20: Fly Intel: Top five analyst initiations

TODAY'S FREE FLY STORIES

Initiation	PPD initiated with an Overweight at Barclays » 18:19 03/02/21 03/02 18:19 03/02/21 18:19 PPD PPD $36.00 / +0.36 (+1.01%) , ICLR Icon $172.19 / -0.78 (-0.45%) Barclays analyst Luke… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events PPD ICLR PPD PPD $36.00 / +0.36 (+1.01%) 02/18/21 PPD awarded US Army study to help develop PTSD drugs 02/09/21 AzurRx BioPharma enters pact with PPD for trial of niclosamide 10/22/20 Moderna says partner PPD 'essential' in Phase 3 Covid study 10/13/20 NeoGenomics to expand global footprint in pharma services ICLR Icon $172.19 / -0.78 (-0.45%) 02/24/21 Icon to acquire PRA Health in $12B cash and stock transaction 02/24/21 Icon to acquire PRA Health in $12B cash and stock transaction 02/16/21 Icon provided update on its CYTO-200 portfolio of clinical programs 01/04/21 Icon provides trial services to Pfizer, BioNTech COVID-19 vaccine program PPD ICLR PPD PPD $36.00 / +0.36 (+1.01%) 16:35 Today Barclays PPD initiated with an Overweight at Barclays 02/25/21 Deutsche Bank PPD price target raised to $39 from $38 at Deutsche Bank 02/25/21 Citi PPD price target raised to $42 from $40 at Citi 10/29/20 Deutsche Bank PPD price target raised to $38 from $33 at Deutsche Bank ICLR Icon $172.19 / -0.78 (-0.45%) 18:08 Today Barclays Icon initiated with an Equal Weight at Barclays 16:34 Today Barclays Icon initiated with an Equal Weight at Barclays 03/01/21 UBS Icon upgraded to Buy from Neutral at UBS 03/01/21 UBS Icon upgraded to Buy from Neutral at UBS PPD ICLR PPD PPD $36.00 / +0.36 (+1.01%) 02/23/21 PPD sees 2021 adjusted EPS $1.37-$1.45, consensus $1.39 02/23/21 PPD sees Q1 adjusted EPS 30c-32c, consensus 32c 02/23/21 PPD reports Q4 adjusted EPS 39c, consensus 36c 10/27/20 PPD sees Q4 revenue $1.26B-$1.3B, consensus $1.15B ICLR Icon $172.19 / -0.78 (-0.45%) 02/24/21 Icon sees FY21 adjusted EPS $8.10-$8.50, consensus $7.94 02/24/21 Icon reports Q4 adjusted EPS $1.90, consensus $1.83 10/21/20 Icon raises FY20 revenue view to $6.35-$6.50 from $6.00-$6.50 10/21/20 Icon reports Q3 EPS $1.72, consensus $1.53 17 Sep PPD ICLR PPD PPD $36.00 / +0.36 (+1.01%) 09/14/20 Fly Intel: After-Hours Movers ICLR Icon $172.19 / -0.78 (-0.45%) 02/24/21 Fly Intel: Pre-market Movers 03/03/21 Icon
Periodicals	GM-backed Cruise in talks to acquire Voyage, Bloomberg reports » 18:19 03/02/21 03/02 18:19 03/02/21 18:19 GM General Motors $54.12 / +1.54 (+2.93%) Cruise, the self-driving… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GM General Motors $54.12 / +1.54 (+2.93%) 02/25/21 Caterpillar elects Gerald Johnson to board of directors 02/17/21 EU passenger car registrations down 24.0% in January 02/16/21 Berkshire Hathaway buys Verizon, exits Barrick Gold in Q4 02/16/21 Cooperman's Omega Advisors buys GM, exits Lee in Q4 GM General Motors $54.12 / +1.54 (+2.93%) 02/19/21 Morgan Stanley GM's 'hidden gems' drawing rising investor interest, says Morgan Stanley 02/18/21 Citi General Motors price target raised to $85 from $70 at Citi 02/16/21 Wedbush Wedbush expects Apple to announce formal EV partnership in 2021 02/11/21 RBC Capital General Motors price target raised to $67 from $52 at RBC Capital GM General Motors $54.12 / +1.54 (+2.93%) 02/10/21 General Motors sees FY21 EBIT-adjusted of $1.5B-$2B 02/10/21 General Motors reports Q4 International EBIT-adjusted of $0.3B 02/10/21 General Motors sees FY21 adjusted EPS $4.50-$5.25, consensus $5.89 02/10/21 General Motors reports Q4 GM North America EBIT-adjusted of $2.6B GM General Motors $54.12 / +1.54 (+2.93%) 18:00 Today GM-backed Cruise in talks to acquire Voyage, Bloomberg reports 02/26/21 GM to furlough workers at Brazil plant for at least 20 days, Reuters reports 02/24/21 GM CFO believes worst of global chip shortage is over, CNBC reports 02/24/21 Biden to address chip shortages with executive action, WSJ reports GM General Motors $54.12 / +1.54 (+2.93%) 02/27/21 Charged: Tesla temporarily halts Model 3 line at CA plant 02/20/21 Charged: Analyst sees Apple announcing EV partnership in 2021 02/10/21 Fly Intel: Wall Street's top stories for Wednesday 02/10/21 Fly Intel: Wall Street's top stories at midday 03/05/21 General Motors - GM GM General Motors $54.12 / +1.54 (+2.93%) 12:25 Today General Motors call volume above normal and directionally bullish 01/28/21 General Motors call volume above normal and directionally bullish 01/20/21 Notable open interest changes for January 20th 01/19/21 Early notable gainers among liquid option names on January 19th
Initiation	Iqvia initiated with an Overweight at Barclays » 18:13 03/02/21 03/02 18:13 03/02/21 18:13 IQV Iqvia $192.72 / -1.69 (-0.87%) Barclays analyst Luke… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options IQV Iqvia $192.72 / -1.69 (-0.87%) 12/21/20 Q2 Solutions teams with Adaptive Biotechnologies to market immunoSEQ Assay 12/16/20 Iqvia in pact with Servier to 'reinvent' its R&D clinical development processes 11/18/20 Iqvia's Rittenmeyer sells over 40,000 common shares 11/13/20 Third Point takes stake in PG&E, boosts Alibaba stake, exits Baxter IQV Iqvia $192.72 / -1.69 (-0.87%) 16:34 Today Barclays Iqvia initiated with an Overweight at Barclays 02/11/21 Truist Iqvia price target raised to $235 from $197 at Truist 02/11/21 Wells Fargo Iqvia price target raised to $230 from $205 at Wells Fargo 02/11/21 Baird Iqvia price target raised to $221 from $208 at Baird IQV Iqvia $192.72 / -1.69 (-0.87%) 02/10/21 Iqvia raises FY21 adjusted EPS view to $7.77-$8.08 from $7.65-$7.95 02/10/21 Iqvia sees Q1 adjusted EPS $1.81-$1.87, consensus $1.80 02/10/21 Iqvia reports Q4 adjusted EPS $2.11, consensus $2.00 02/09/21 Notable companies reporting before tomorrow's open IQV Iqvia $192.72 / -1.69 (-0.87%) 02/10/21 Fly Intel: Pre-market Movers 10/20/20 Fly Intel: Pre-market Movers 04/13/21 IQVIA Holdings Inc. IQV Iqvia $192.72 / -1.69 (-0.87%) 02/10/21 Early notable gainers among liquid option names on February 10th
Initiation	Icon initiated with an Equal Weight at Barclays » 18:08 03/02/21 03/02 18:08 03/02/21 18:08 ICLR Icon $172.19 / -0.78 (-0.45%) , PRAH PRA Health $142.89 / -1.13 (-0.78%) Barclays analyst Luke… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events ICLR PRAH ICLR Icon $172.19 / -0.78 (-0.45%) 02/24/21 Icon to acquire PRA Health in $12B cash and stock transaction 02/24/21 Icon to acquire PRA Health in $12B cash and stock transaction 02/16/21 Icon provided update on its CYTO-200 portfolio of clinical programs 01/04/21 Icon provides trial services to Pfizer, BioNTech COVID-19 vaccine program PRAH PRA Health $142.89 / -1.13 (-0.78%) 02/24/21 Icon to acquire PRA Health in $12B cash and stock transaction 02/24/21 Icon to acquire PRA Health in $12B cash and stock transaction 12/17/20 PRA Health partners with Fulgent Genetics to enhance COVID-19 monitoring program 12/02/20 Appili Therapeutics doses first participant in Avigan trial ICLR PRAH ICLR Icon $172.19 / -0.78 (-0.45%) 16:34 Today Barclays Icon initiated with an Equal Weight at Barclays 03/01/21 UBS Icon upgraded to Buy from Neutral at UBS 03/01/21 UBS Icon upgraded to Buy from Neutral at UBS 02/26/21 Truist Icon upgraded to Buy from Hold at Truist PRAH PRA Health $142.89 / -1.13 (-0.78%) 03/01/21 UBS Icon upgraded to Buy from Neutral at UBS 02/26/21 Truist Icon upgraded to Buy from Hold at Truist 02/25/21 Jefferies PRA Health downgraded to Hold from Buy at Jefferies 02/25/21 Deutsche Bank Icon price target raised to $208 from $179 at Deutsche Bank ICLR PRAH ICLR Icon $172.19 / -0.78 (-0.45%) 02/24/21 Icon sees FY21 adjusted EPS $8.10-$8.50, consensus $7.94 02/24/21 Icon reports Q4 adjusted EPS $1.90, consensus $1.83 10/21/20 Icon raises FY20 revenue view to $6.35-$6.50 from $6.00-$6.50 10/21/20 Icon reports Q3 EPS $1.72, consensus $1.53 PRAH PRA Health $142.89 / -1.13 (-0.78%) 02/24/21 PRA Health reports Q4 adjusted EPS $1.55, consensus $1.47 11/04/20 PRA Health raises FY20 adj. EPS view to $4.61-$4.71 from $4.35-$4.55 11/04/20 PRA Health reports Q3 adj. EPS $1.30, consensus $1.12 ICLR PRAH ICLR Icon $172.19 / -0.78 (-0.45%) 02/24/21 Fly Intel: Pre-market Movers PRAH PRA Health $142.89 / -1.13 (-0.78%) 02/24/21 Fly Intel: Pre-market Movers 03/03/21 Icon
Periodicals	Goldman Sachs' general counsel, Karen Seymour, to leave, Bloomberg reports » 18:08 03/02/21 03/02 18:08 03/02/21 18:08 GS Goldman Sachs $330.86 / +0.975 (+0.30%) Karen Seymour, Goldman… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GS Goldman Sachs $330.86 / +0.975 (+0.30%) 08:03 Today Goldman Sachs, Hazeltree partner for streamlined treasury, global payments 02/19/21 Goldman Sachs CFO sells 20K shares of common stock 02/02/21 Goldman Sachs officer Laurence Stein sold almost $3M in company shares 02/01/21 Northrop Grumman announces $2B accelerated share repurchase program GS Goldman Sachs $330.86 / +0.975 (+0.30%) 02/24/21 Wells Fargo Goldman Sachs price target raised to $360 from $335 at Wells Fargo 01/28/21 Deutsche Bank Goldman Sachs price target raised to $310 from $290 at Deutsche Bank 01/22/21 Citi Goldman Sachs price target raised to $370 from $357 at Citi 01/20/21 Credit Suisse Goldman Sachs price target raised to $345 from $325 at Credit Suisse GS Goldman Sachs $330.86 / +0.975 (+0.30%) 01/19/21 Goldman Sachs reports Q4 EPS $12.08, consensus $7.47 01/18/21 Fly Intel: What to watch in next round of big banks' earnings reports 10/14/20 Goldman Sachs reports Q3 EPS $9.68, consensus $5.57 10/13/20 Notable companies reporting before tomorrow's open GS Goldman Sachs $330.86 / +0.975 (+0.30%) 03/01/21 Goldman reboots crypto trading desk amid institutional interest, Reuters reports 03/01/21 Goldman co-head of asset management leaving firm, Bloomberg reports 03/01/21 Goldman's Omer Ismail leaving to run Walmart's fintech startup, WSJ reports 02/22/21 Toast planning IPO that could value it at around $20B, WSJ reports GS Goldman Sachs $330.86 / +0.975 (+0.30%) 02/05/21 The Intersection: Crypto and Wall Street This Week 01/21/21 Fly Intel: What to watch in IBM's earnings report 01/19/21 Fly Intel: Wall Street's top stories at midday 01/19/21 Fly Intel: Pre-market Movers 03/01/21 46th Annual Virtual Conference of AIFA 2021 03/25/21 REITwise 2021 Virtual Conference 04/14/21 Goldman Sachs - GS 03/04/21 Goldman Sachs Group Inc. GS Goldman Sachs $330.86 / +0.975 (+0.30%) 01/13/21 Unusual call flow in option market yesterday 01/12/21 Short term 300 strike calls in Goldman Sachs see early action 01/07/21 Goldman Sachs call volume above normal and directionally bullish 12/23/20 Unusually active option classes on open December 23rd

Periodicals	Biden's pick for SEC chief gives views on cryptocurrency oversight, Quarts says » 18:06 03/02/21 03/02 18:06 03/02/21 18:06 BTC Bitcoin $0.00 / + (+0.00%) , BITCOIN Bitcoin $0.00 / + (+0.00%) , GBTC Bitcoin Investment Trust $0.00 / + (+0.00%) President Joe… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly BTC BITCOIN BTC Bitcoin $0.00 / + (+0.00%) 02/12/21 Twitter CEO, Jay-Z partner to establish bitcoin development fund 02/11/21 BNY Mellon announces formation of new digital assets unit 02/10/21 MasterCard to start support select cryptocurrencies on its network 02/10/21 Twitter CFO to CNBC's 'Squawk Box': Company has studied using bitcoin BITCOIN Bitcoin $0.00 / + (+0.00%) 02/12/21 Twitter CEO, Jay-Z partner to establish bitcoin development fund 02/11/21 BNY Mellon announces formation of new digital assets unit 02/10/21 MasterCard to start support select cryptocurrencies on its network 02/10/21 Twitter CFO to CNBC's 'Squawk Box': Company has studied using bitcoin BTC BITCOIN GBTC BTC Bitcoin $0.00 / + (+0.00%) 01/13/21 Standpoint Research Bitcoin could hit $112,000 this year, says Standpoint Research BITCOIN Bitcoin $0.00 / + (+0.00%) GBTC Bitcoin Investment Trust $0.00 / + (+0.00%) BTC BITCOIN GBTC BTC Bitcoin $0.00 / + (+0.00%) 03/01/21 Goldman reboots crypto trading desk amid institutional interest, Reuters reports 02/24/21 Square CFO says Cash App saw surge in new bitcoin buyers in January, CNBC says 02/19/21 'Heard on the Street' highlights PayPal, Square among crypto-exposure names 02/15/21 Morgan Stanley investing arm weighs adding Bitcoin to bets list, Bloomberg says BITCOIN Bitcoin $0.00 / + (+0.00%) 03/01/21 Goldman reboots crypto trading desk amid institutional interest, Reuters reports 02/24/21 Square CFO says Cash App saw surge in new bitcoin buyers in January, CNBC says 02/19/21 'Heard on the Street' highlights PayPal, Square among crypto-exposure names 02/12/21 Uber would consider accepting bitcoin, CEO tells CNBC GBTC Bitcoin Investment Trust $0.00 / + (+0.00%) 03/01/21 Goldman reboots crypto trading desk amid institutional interest, Reuters reports 01/20/21 Janet Yellen says cryptocurrencies used for illegal financing, BI says 09/29/20 Grayscale now controls roughly 2.4% of total Bitcoin supply, Cointelegraph says BTC BITCOIN BTC Bitcoin $0.00 / + (+0.00%) 02/27/21 Charged: Tesla temporarily halts Model 3 line at CA plant 02/26/21 The Intersection: Crypto and Wall Street This Week 02/24/21 Fly Intel: Wall Street's top stories for Wednesday 02/19/21 The Intersection: Crypto and Wall Street This Week BITCOIN Bitcoin $0.00 / + (+0.00%) 02/26/21 The Intersection: Crypto and Wall Street This Week 02/24/21 Fly Intel: Wall Street's top stories for Wednesday 02/19/21 The Intersection: Crypto and Wall Street This Week 02/17/21 Fly Intel: Wall Street's top stories at midday
Hot Stocks	Mayville Engineering not providing financial outlook for 2021 » 18:02 03/02/21 03/02 18:02 03/02/21 18:02 MEC Mayville Engineering $15.15 / +0.44 (+2.99%) Based on the ongoing… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events MEC Mayville Engineering $15.15 / +0.44 (+2.99%) 11/02/20 Mayville Engineering is not providing financial outlook MEC Mayville Engineering $15.15 / +0.44 (+2.99%) 02/04/21 Baird Mayville Engineering price target raised to $20 from $14 at Baird 11/04/20 Citi Mayville Engineering price target raised to $13 from $10 at Citi 08/21/20 Fly Intel: Top five analyst upgrades 08/21/20 UBS Mayville Engineering upgraded to Buy from Neutral at UBS MEC Mayville Engineering $15.15 / +0.44 (+2.99%) 18:02 Today Mayville Engineering reports Q4 pro forma EPS 5c, consensus 1c 11/02/20 Mayville Engineering reports Q3 pro forma EPS (5c), consensus (4c) 03/03/21 Mayville Engineering - MEC
Earnings	Mayville Engineering reports Q4 pro forma EPS 5c, consensus 1c » 18:02 03/02/21 03/02 18:02 03/02/21 18:02 MEC Mayville Engineering $15.15 / +0.44 (+2.99%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events MEC Mayville Engineering $15.15 / +0.44 (+2.99%) 11/02/20 Mayville Engineering is not providing financial outlook MEC Mayville Engineering $15.15 / +0.44 (+2.99%) 02/04/21 Baird Mayville Engineering price target raised to $20 from $14 at Baird 11/04/20 Citi Mayville Engineering price target raised to $13 from $10 at Citi 08/21/20 Fly Intel: Top five analyst upgrades 08/21/20 UBS Mayville Engineering upgraded to Buy from Neutral at UBS MEC Mayville Engineering $15.15 / +0.44 (+2.99%) 11/02/20 Mayville Engineering reports Q3 pro forma EPS (5c), consensus (4c) 03/03/21 Mayville Engineering - MEC
Initiation	Thermo Fisher initiated with an Overweight at Barclays » 18:01 03/02/21 03/02 18:01 03/02/21 18:01 TMO Thermo Fisher $462.24 / +2.7 (+0.59%) Barclays analyst Luke… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events TMO Thermo Fisher $462.24 / +2.7 (+0.59%) 02/26/21 Thermo Fisher: Mesa Biotech acquisition to add about $200M in revenue in 2021 02/23/21 Thermo Fisher increases quarterly cash dividend 18% to 26c per share 02/17/21 Thermo Fisher acquires cell sorting technology assets from Propel Labs 02/01/21 Thermo Fisher CEO: We are well-positioned in high growth areas TMO Thermo Fisher $462.24 / +2.7 (+0.59%) 16:36 Today Barclays Thermo Fisher initiated with an Overweight at Barclays 02/09/21 Wells Fargo Qiagen shares should be sold on latest merger talk, says Wells Fargo 02/03/21 BTIG Thermo Fisher price target raised to $590 from $540 at BTIG 02/02/21 SVB Leerink Thermo Fisher price target raised to $560 from $525 at SVB Leerink TMO Thermo Fisher $462.24 / +2.7 (+0.59%) 02/01/21 Thermo Fisher sees FY21 EPS $21.62, consensus $20.74 02/01/21 Thermo Fisher reports Q4 adjusted EPS $7.09, consensus $6.56 12/01/20 Thermo Fisher raises FY20 adjusted EPS view to $19.17, consensus $18.34 10/21/20 Thermo Fisher sees FY20 EPS $18.27, consensus $15.92 TMO Thermo Fisher $462.24 / +2.7 (+0.59%) 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports TMO Thermo Fisher $462.24 / +2.7 (+0.59%) 02/01/21 Fly Intel: Pre-market Movers 12/01/20 Fly Intel: Wall Street's top stories for Tuesday 10/21/20 Fly Intel: Pre-market Movers 09/14/20 GameStop upgrades, MGM downgrade among today's top calls on Wall Street 00:00 Today 41st Annual Healthcare Virtual Conference
Periodicals	GM-backed Cruise in talks to acquire Voyage, Bloomberg reports » 18:00 03/02/21 03/02 18:00 03/02/21 18:00 GM General Motors $54.12 / +1.54 (+2.93%) Cruise, the self-driving… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GM General Motors $54.12 / +1.54 (+2.93%) 02/25/21 Caterpillar elects Gerald Johnson to board of directors 02/17/21 EU passenger car registrations down 24.0% in January 02/16/21 Berkshire Hathaway buys Verizon, exits Barrick Gold in Q4 02/16/21 Cooperman's Omega Advisors buys GM, exits Lee in Q4 GM General Motors $54.12 / +1.54 (+2.93%) 02/19/21 Morgan Stanley GM's 'hidden gems' drawing rising investor interest, says Morgan Stanley 02/18/21 Citi General Motors price target raised to $85 from $70 at Citi 02/16/21 Wedbush Wedbush expects Apple to announce formal EV partnership in 2021 02/11/21 RBC Capital General Motors price target raised to $67 from $52 at RBC Capital GM General Motors $54.12 / +1.54 (+2.93%) 02/10/21 General Motors sees FY21 EBIT-adjusted of $1.5B-$2B 02/10/21 General Motors reports Q4 International EBIT-adjusted of $0.3B 02/10/21 General Motors sees FY21 adjusted EPS $4.50-$5.25, consensus $5.89 02/10/21 General Motors reports Q4 GM North America EBIT-adjusted of $2.6B GM General Motors $54.12 / +1.54 (+2.93%) 02/26/21 GM to furlough workers at Brazil plant for at least 20 days, Reuters reports 02/24/21 GM CFO believes worst of global chip shortage is over, CNBC reports 02/24/21 Biden to address chip shortages with executive action, WSJ reports 02/02/21 'Apple Car' to use E-GMP platform from Hyundai, Apple Insider reports GM General Motors $54.12 / +1.54 (+2.93%) 02/27/21 Charged: Tesla temporarily halts Model 3 line at CA plant 02/20/21 Charged: Analyst sees Apple announcing EV partnership in 2021 02/10/21 Fly Intel: Wall Street's top stories for Wednesday 02/10/21 Fly Intel: Wall Street's top stories at midday 03/05/21 General Motors - GM GM General Motors $54.12 / +1.54 (+2.93%) 12:25 Today General Motors call volume above normal and directionally bullish 01/28/21 General Motors call volume above normal and directionally bullish 01/20/21 Notable open interest changes for January 20th 01/19/21 Early notable gainers among liquid option names on January 19th

Initiation	Sotera Health initiated with an Overweight at Barclays » 17:53 03/02/21 03/02 17:53 03/02/21 17:53 SHC Sotera Health $26.62 / -0.91 (-3.31%) Barclays analyst Luke… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly SHC Sotera Health $26.62 / -0.91 (-3.31%) 12/18/20 Sotera Health announces debt pay down, expansion of revolving credit facility SHC Sotera Health $26.62 / -0.91 (-3.31%) 16:35 Today Barclays Sotera Health initiated with an Overweight at Barclays 01/13/21 Baird Sotera Health initiated with an Outperform at Baird 12/15/20 KeyBanc Sotera Health initiated with an Overweight at KeyBanc 12/15/20 JPMorgan Sotera Health initiated with an Overweight at JPMorgan SHC Sotera Health $26.62 / -0.91 (-3.31%) 01/11/21 Sotera Health reports preliminary 2020 revenue $817M, consensus $814.05M 01/11/21 Sotera Health reports preliminary Q4 revenue $216M, consensus $206.91M 20 Nov SHC Sotera Health $26.62 / -0.91 (-3.31%) 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO
Initiation	Ortho Clinical Diagnostics initiated with an Overweight at Barclays » 17:46 03/02/21 03/02 17:46 03/02/21 17:46 OCDX Ortho Clinical Diagnostics $17.58 / -0.02 (-0.11%) Barclays analyst Luke… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Syndicate On The Fly Options OCDX Ortho Clinical Diagnostics $17.58 / -0.02 (-0.11%) 16:35 Today Barclays Ortho Clinical Diagnostics initiated with an Overweight at Barclays 02/22/21 Fly Intel: Top five analyst initiations 02/22/21 Evercore ISI Ortho Clinical Diagnostics initiated with an Outperform at Evercore ISI 02/22/21 Credit Suisse Ortho Clinical Diagnostics initiated with an Outperform at Credit Suisse 28 Jan OCDX Ortho Clinical Diagnostics $17.58 / -0.02 (-0.11%) 01/31/21 Opening Day: Qualtrics jumps 40% in trading debut OCDX Ortho Clinical Diagnostics $17.58 / -0.02 (-0.11%) 02/18/21 Fourteen new option listings and one option delisting on February 18th
Hot Stocks	Rio Tinto chairman Thompson to not seek re-election as board director » 17:45 03/02/21 03/02 17:45 03/02/21 17:45 RIO Rio Tinto $91.27 / +1.43 (+1.59%) Rio Tinto chairman Simon… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals Options RIO Rio Tinto $91.27 / +1.43 (+1.59%) 05:32 Today Rio Tinto to dispute ATO amended assessments of $279.8M tax, $36.7M interest 02/26/21 Rio Tinto has awarded over $385M in contracts for Greater Tom Price Operations 02/16/21 Rio Tinto and Hydro announce intention to close Aluchemie anode plant 02/16/21 Rio Tinto, Paul Wurth and SHS sign MOU to explore low-carbon steel feedstock RIO Rio Tinto $91.27 / +1.43 (+1.59%) 02/18/21 UBS Rio Tinto price target raised to 5,800 GBp from 5,500 GBp at UBS 02/09/21 JPMorgan Rio Tinto price target raised to 7,120 GBp from 6,940 GBp at JPMorgan 02/08/21 JPMorgan Rio Tinto price target lowered to 6,940 GBp from 7,000 GBp at JPMorgan 02/05/21 Fly Intel: Top five analyst initiations RIO Rio Tinto $91.27 / +1.43 (+1.59%) 02/18/21 Rio Tinto willing to enter new agreement with Mongolia, Reuters says 11/25/20 Mongolia seeks review on Rio Tinto's Oyu Tolgoi mine, FT reports 10/15/20 Newmont CEO not interested in Rio Tinto chief job, FT reports RIO Rio Tinto $91.27 / +1.43 (+1.59%) 12/24/20 Unusual call flow in option market yesterday 12/23/20 One year call upside position opened in Rio Tinto
Periodicals	Toyota does not plan to ask Texas workers to stop wearing masks, Reuters says » 17:44 03/02/21 03/02 17:44 03/02/21 17:44 TM Toyota $149.30 / +0.025 (+0.02%) Toyota currently does not… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly TM Toyota $149.30 / +0.025 (+0.02%) 02/18/21 Toyota West Virginia announces $210M investment, 100 new jobs 02/17/21 EU passenger car registrations down 24.0% in January 02/16/21 Toyota to temporarily halt production at 9 factories in Japan after earthquake 02/10/21 Toyota to debut three new EVs for U.S. market in 2021 TM Toyota $149.30 / +0.025 (+0.02%) 09/14/20 Credit Suisse Toyota upgraded to Outperform from Neutral at Credit Suisse 09/08/20 Bernstein Bernstein sees Tesla's current valuation as 'mind-boggling' 07/29/20 Morgan Stanley Tesla price target raised to $1,050 from $740 at Morgan Stanley 07/28/20 Macquarie Toyota initiated with an Underperform at Macquarie TM Toyota $149.30 / +0.025 (+0.02%) 02/10/21 Toyota reports nine months EPS Y525.23 vs. Y608.73 last year 11/06/20 Toyota sees FY21 sales revenue Y26T, operating income Y1.3B 11/06/20 Toyota reports 1H EPS Y223.81 vs. Y403.51 last year TM Toyota $149.30 / +0.025 (+0.02%) 09:15 Today Toyota reports February U.S. sales down 5.7%, Bloomberg says 03/01/21 U.S. regulators open probe into 1.9M Toyota RAV 4 vehicles, Reuters says 02/16/21 Toyota to temporarily halt production at nine factories in Japan, Reuters says 02/03/21 Toyota aims to produce 9.2M vehicles in 2021, Nikkei reports TM Toyota $149.30 / +0.025 (+0.02%) 09/22/20 Tesla slips ahead of Battery Day as Musk says 'serious' output not until 2022 09/16/20 Casino stocks downgrades, Tesla target increases among top calls on Wall Street
Initiation	Illumina started with an Underweight at Barclays on near-term growth issues » 17:42 03/02/21 03/02 17:42 03/02/21 17:42 ILMN Illumina $441.51 / -4.8 (-1.08%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ILMN Illumina $441.51 / -4.8 (-1.08%) 07:55 Today Myriad Genetics partners with Intermountain Precision Genomics 02/19/21 Illumina, University Hospital of Tubingen to evaluate WGS potential 02/08/21 Illumina accelerator invests in nine genomics startups for second global cycle 02/04/21 Illumina announces agreement with Belgian Society of Medical Oncology ILMN Illumina $441.51 / -4.8 (-1.08%) 16:30 Today Barclays Illumina initiated with an Underweight at Barclays 02/16/21 BTIG Illumina price target raised to $570 from $410 at BTIG 02/12/21 Piper Sandler Illumina price target raised to $510 from $415 at Piper Sandler 02/12/21 Cowen Illumina price target raised to $460 from $385 at Cowen ILMN Illumina $441.51 / -4.8 (-1.08%) 02/11/21 Illumina sees FY21 adjusted EPS $5.10-$5.35, consensus $6.11 02/11/21 Illumina reports Q4 adjusted EPS $1.22, consensus $1.11 02/11/21 Notable companies reporting after market close 01/11/21 Illumina sees FY21 adjusted EPS $5.10-$5.35, consensus $6.61 ILMN Illumina $441.51 / -4.8 (-1.08%) 09/16/20 Illumina near deal to acquire cancer testing company Grail, Bloomberg reports ILMN Illumina $441.51 / -4.8 (-1.08%) 10/29/20 Fly Intel: After-Hours Movers 09/21/20 Fly Intel: Wall Street's top stories for Monday 09/21/20 Fly Intel: Wall Street's top stories at midday 09/21/20 Fly Intel: Pre-market Movers 00:00 Today 41st Annual Healthcare Virtual Conference ILMN Illumina $441.51 / -4.8 (-1.08%) 02/12/21 Early notable gainers among liquid option names on February 12th 01/15/21 Early notable gainers among liquid option names on January 15th 12/22/20 Early notable gainers among liquid option names on December 22nd 09/22/20 Illumina call volume above normal and directionally bullish

Upgrade	Sensata upgraded to Overweight at JPMorgan on auto electrification/connectivity » 17:35 03/02/21 03/02 17:35 03/02/21 17:35 ST Sensata $59.66 / +0.42 (+0.71%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events ST Sensata $59.66 / +0.42 (+0.71%) 02/12/21 Sensata to acquire Xirgo Technologies for $400M, sees accretion 02/02/21 Sensata acquires Lithium Balance, terms undisclosed 12/04/20 Sensata signs strategic long-term agreement with Carrier Global 11/10/20 Sensata CTO sells 21,485 ordinary shares ST Sensata $59.66 / +0.42 (+0.71%) 16:59 Today JPMorgan Sensata upgraded to Overweight from Neutral at JPMorgan 01/22/21 Barclays Sensata price target raised to $65 from $55 at Barclays 12/14/20 Morgan Stanley Sensata upgraded to Overweight on dollar content growth at Morgan Stanley 12/14/20 Morgan Stanley Sensata upgraded to Overweight from Equal Weight at Morgan Stanley ST Sensata $59.66 / +0.42 (+0.71%) 02/02/21 Sensata sees FY21 adjusted EPS $3.06-$3.42, consensus $3.26 02/02/21 Sensata sees Q1 adjusted EPS 67c-77c, consensus 74c 02/02/21 Sensata reports Q4 adjusted EPS 85c, consensus 78c 01/08/21 Sensata raises Q4 revenue view to $902M-$907M from $810M-$850M ST Sensata $59.66 / +0.42 (+0.71%) 01/08/21 Fly Intel: Pre-market Movers 00:00 Today Industrial Technologies Virtual Conference 2021
Initiation	Danaher started at Overweight at Barclays on GE biopharma business potential » 17:29 03/02/21 03/02 17:29 03/02/21 17:29 DHR Danaher $224.05 / -1.54 (-0.68%) , GE General Electric $12.98 / -0.135 (-1.03%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options DHR GE DHR Danaher $224.05 / -1.54 (-0.68%) 16:36 Today Director of Danaher Mitchell Rales purchases $1.4M in shares 01/13/21 Danaher expects Q4 revenue up approx. 38.5% y-o-y, consensus $6.44B 12/21/20 Danaher names Jose-Carlos Gutierrez-Ramos as Chief Scientific Officer 12/18/20 Danaher operating company launches COVID-19 antigen test GE General Electric $12.98 / -0.135 (-1.03%) 02/24/21 Altair acquires Flow Simulator sofftware from GE Aviation 02/17/21 General Electric focusing on growing through existing business lines, CEO says 02/17/21 General Electric CEO says unlikely to do large M&A deals soon 02/12/21 Trian Fund exits nVent, increases stake in GE DHR GE DHR Danaher $224.05 / -1.54 (-0.68%) 16:33 Today Barclays Danaher initiated with an Overweight at Barclays 01/06/21 Cowen Danaher named a top diversified pick at Cowen 01/04/21 Evercore ISI Danaher added to Core Ideas List at Evercore ISI 12/02/20 Goldman Sachs Danaher initiated with a Buy at Goldman Sachs GE General Electric $12.98 / -0.135 (-1.03%) 02/22/21 Goldman Sachs General Electric price target raised to $15 at Goldman Sachs after meetings 01/28/21 Barclays General Electric price target raised to $13 from $12 at Barclays 01/27/21 Morgan Stanley General Electric price target raised to $13 from $12 at Morgan Stanley 01/27/21 Citi General Electric developing track record of delivering, says Citi DHR GE DHR Danaher $224.05 / -1.54 (-0.68%) 01/28/21 Danaher reports Q4 non-GAAP EPS $2.08, consensus $1.87 01/27/21 Notable companies reporting before tomorrow's open 01/27/21 Notable companies reporting before tomorrow's open 10/22/20 Danaher reports Q3 adj. EPS 1.72, consensus $1.36 GE General Electric $12.98 / -0.135 (-1.03%) 01/26/21 General Electric sees FY21 adjusted EPS 15c-25c, consensus 38c 01/26/21 General Electric reports Q4 adjusted EPS 8c, consensus 9c 01/25/21 Notable companies reporting before tomorrow's open 01/25/21 Notable companies reporting before tomorrow's open 08 May DHR GE DHR Danaher $224.05 / -1.54 (-0.68%) 09/26/20 Fortive spinning off a business, time to buy stock, Barron's says GE General Electric $12.98 / -0.135 (-1.03%) 02/16/21 General Electric sees negative cash flow in Q1, Reuters reports 02/11/21 Southwest in talks for at least 300 new 150-seat planes, Air Current says 01/14/21 GE says Siemens stole trade secrets in bid to rig contracts , Reuters reports 01/11/21 GE to pause donations to lawmakers who voted against Biden win, Bloomberg says GE GE General Electric $12.98 / -0.135 (-1.03%) 01/27/21 Nokia soars but company 'not aware' of apparent reason for trading activity 01/26/21 Fly Intel: Wall Street's top stories for Tuesday 01/26/21 Fly Intel: Pre-market Movers 11/24/20 Target upgrade, Microsoft initiation among today's top calls on Wall Street 03/10/21 General Electric Co. DHR GE DHR Danaher $224.05 / -1.54 (-0.68%) 01/22/21 Early notable gainers among liquid option names on January 22nd GE General Electric $12.98 / -0.135 (-1.03%) 02/24/21 General Electric call volume above normal and directionally bullish 01/26/21 Early notable gainers among liquid option names on January 26th 01/06/21 General Electric call volume above normal and directionally bullish 12/23/20 Notable open interest changes for December 23rd
Initiation	Barclays starts Avantor at Overweight on accelerating growth, margin expansion » 17:22 03/02/21 03/02 17:22 03/02/21 17:22 AVTR Avantor $28.75 / +0.275 (+0.97%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate AVTR Avantor $28.75 / +0.275 (+0.97%) 02/16/21 Third Point buys Upstart, exits Caesars in Q4 11/19/20 Avantor opens new biorepository facility in Europe 11/02/20 Avantor announces presentations at Cell & Gene Therapy conference AVTR Avantor $28.75 / +0.275 (+0.97%) 16:32 Today Barclays Avantor initiated with an Overweight at Barclays 02/04/21 Avantor price target raised to $35 from $33 at Citi 02/04/21 Piper Sandler Avantor price target raised to $28 from $21 at Piper Sandler 01/19/21 KeyBanc Avantor price target raised to $40 from $33 at KeyBanc AVTR Avantor $28.75 / +0.275 (+0.97%) 02/03/21 Avantor reports Q4 adjusted EPS 29c, consensus 26c 01/11/21 Avantor reports preliminary Q4 revenue $1.79B, consensus $1.62B 10/27/20 Avantor reports Q3 adjusted EPS 24c, consensus 21c 10/23/20 Avantor reports preliminary Q3 revenue $1.6B, consensus $1.54B 06 Nov 20 Aug 21 May
Upgrade	JPMorgan upgrades Casa Systems to Neutral on better diversification » 17:15 03/02/21 03/02 17:15 03/02/21 17:15 CASA Casa Systems $8.03 / -0.47 (-5.53%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CASA Casa Systems $8.03 / -0.47 (-5.53%) 01/19/21 Izzi deploys Casa's Axyom Virtual Broadband Network Gateway 12/11/20 Casa Systems joins Telecom Infra Project's OpenBNG initiative 12/08/20 Casa Systems announces Software AG Cumulocity IoT partnership 09/09/20 Casa Systems unveils high-power 5G mmWave CPE CASA Casa Systems $8.03 / -0.47 (-5.53%) 17:02 Today JPMorgan Casa Systems upgraded to Neutral from Underweight at JPMorgan 02/19/21 Northland Casa Systems price target raised to $12 from $9 at Northland 01/14/21 Barclays Casa Systems upgraded to Overweight with $9 target at Barclays 01/14/21 Barclays Casa Systems upgraded to Overweight from Equal Weight at Barclays CASA Casa Systems $8.03 / -0.47 (-5.53%) 02/18/21 Casa Systems sees FY21 EPS 23c-32c, consensus 31cc 02/18/21 Casa Systems reports Q4 EPS 27c, consensus 11c 02/18/21 Casa Systems reports Q4 EPS 27c, consensus 11c 10/28/20 Casa Systems raises FY20 EPS view to 9c-14c from 0c-12c, consensus 6c CASA Casa Systems $8.03 / -0.47 (-5.53%) 02/19/21 Fly Intel: Wall Street's top stories for Friday 02/19/21 Fly Intel: Wall Street's top stories at midday 02/18/21 Fly Intel: After-Hours Movers 10/28/20 Fly Intel: After-Hours Movers
Syndicate	Axos Financial files to sell $50M of common stock for holders 17:15 03/02/21 03/02 17:15 03/02/21 17:15 AX Axos Financial $47.39 / -0.42 (-0.88%) ShowHide Related Items >><< Street Research Earnings On The Fly AX Axos Financial $47.39 / -0.42 (-0.88%) 01/29/21 B. Riley Securities Axos Financial price target raised to $48 from $45 at B. Riley Securities 01/15/21 Janney Montgomery Scott Janney Montgomery Scott starts 'well-positioned' Axos Financial at Buy 01/15/21 DA Davidson Axos Financial price target raised to $48 from $42 at DA Davidson 01/15/21 Janney Montgomery Scott Axos Financial initiated with a Buy at Janney Montgomery Scott AX Axos Financial $47.39 / -0.42 (-0.88%) 01/28/21 Axos Financial reports Q2 adjusted EPS 94c, consensus 83c 10/29/20 Axos Financial reports Q1 adjusted EPS 91c, consensus 68c AX Axos Financial $47.39 / -0.42 (-0.88%) 10/29/20 Fly Intel: After-Hours Movers

Syndicate	Axos Financial files $400M mixed securities shelf 17:14 03/02/21 03/02 17:14 03/02/21 17:14 AX Axos Financial $47.39 / -0.42 (-0.88%) ShowHide Related Items >><< Street Research Earnings On The Fly AX Axos Financial $47.39 / -0.42 (-0.88%) 01/29/21 B. Riley Securities Axos Financial price target raised to $48 from $45 at B. Riley Securities 01/15/21 Janney Montgomery Scott Janney Montgomery Scott starts 'well-positioned' Axos Financial at Buy 01/15/21 DA Davidson Axos Financial price target raised to $48 from $42 at DA Davidson 01/15/21 Janney Montgomery Scott Axos Financial initiated with a Buy at Janney Montgomery Scott AX Axos Financial $47.39 / -0.42 (-0.88%) 01/28/21 Axos Financial reports Q2 adjusted EPS 94c, consensus 83c 10/29/20 Axos Financial reports Q1 adjusted EPS 91c, consensus 68c AX Axos Financial $47.39 / -0.42 (-0.88%) 10/29/20 Fly Intel: After-Hours Movers
Hot Stocks	Chairman of American Assets Trust Rady purchases 12,200 shares of company stock » 17:08 03/02/21 03/02 17:08 03/02/21 17:08 AAT American Assets Trust $32.46 / +0.505 (+1.58%) Chairman of American… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research AAT American Assets Trust $32.46 / +0.505 (+1.58%) 02/22/21 American Assets Trust CEO buys 118K shares of common stock 12/02/20 American Assets Trust CEO buys 50.1K shares of common stock 11/06/20 American Assets Trust CEO buys 130K shares of common stock AAT American Assets Trust $32.46 / +0.505 (+1.58%) 05/21/20 Wells Fargo American Assets Trust price target lowered to $30 from $51 at Wells Fargo 05/18/20 Morgan Stanley Morgan Stanley downgrades American Assets Trust to Equal Weight, halves target 05/18/20 Morgan Stanley American Assets downgraded to Equal Weight from Overweight at Morgan Stanley
Hot Stocks	Point72 Asset Management reports 5.5% passive stake in Paya Holdings » 17:07 03/02/21 03/02 17:07 03/02/21 17:07 PAYA Paya Holdings $12.44 / -0.16 (-1.27%) Point72 Asset Management… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events PAYA Paya Holdings $12.44 / -0.16 (-1.27%) 02/25/21 Paya's FIrst Billings Services, Agent 511 announce strategic partnership 02/09/21 Paya Holdings' payment solution certified by Acumatica 11/02/20 Paya Holdings appoints Matt Humphries as head of investor relations 10/27/20 Paya Holdings partners with Artis Technologies PAYA Paya Holdings $12.44 / -0.16 (-1.27%) 02/26/21 Raymond James Paya Holdings initiated with an Outperform at Raymond James 02/23/21 DA Davidson Paya Holdings initiated with a Buy at DA Davidson 02/23/21 DA Davidson Paya Holdings initiated with a Buy at DA Davidson 01/13/21 Fly Intel: Top five analyst initiations PAYA Paya Holdings $12.44 / -0.16 (-1.27%) 11/09/20 Paya Holdings reports Q3 revenue $51.8M, consensus $53.35M 03/23/21 Paya Holdings
Recommendations	Helios Technologies price target raised to $82 from $72 at Baird » 17:05 03/02/21 03/02 17:05 03/02/21 17:05 HLIO Helios Technologies $68.89 / +1.295 (+1.92%) Baird analyst Mircea… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events HLIO Helios Technologies $68.89 / +1.295 (+1.92%) 01/21/21 Helios Technologies to acquire BJN Technologies, terms undisclosed 10/12/20 Helios Technologies to acquire Balboa Water Group for $218.5M HLIO Helios Technologies $68.89 / +1.295 (+1.92%) 10/12/20 Baird Helios Technologies upgraded to Outperform from Neutral at Baird 05/29/20 Morgan Stanley Morgan Stanley upgrades Helios to Equal Weight following underperformance 05/29/20 Morgan Stanley Helios Technologies upgraded to Equal Weight from Underweight at Morgan Stanley 03/27/20 SunTrust Helios Technologies price target lowered to $36 from $45 at SunTrust HLIO Helios Technologies $68.89 / +1.295 (+1.92%) 03/01/21 Helios Technologies reports Q4 EPS 60c, consensus 41c 11/02/20 Helios Technologies sees FY20 revenue $485M-$495M, consensus $486.24M 11/02/20 Helios Technologies reports Q3 adjusted EPS 53c, consensus 41c HLIO Helios Technologies $68.89 / +1.295 (+1.92%) 03/01/21 Fly Intel: After-Hours Movers 09:00 Today Helios Technologies - HLIO
Upgrade	Casa Systems upgraded to Neutral from Underweight at JPMorgan » 17:02 03/02/21 03/02 17:02 03/02/21 17:02 CASA Casa Systems $8.03 / -0.47 (-5.53%) JPMorgan analyst Samik… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CASA Casa Systems $8.03 / -0.47 (-5.53%) 01/19/21 Izzi deploys Casa's Axyom Virtual Broadband Network Gateway 12/11/20 Casa Systems joins Telecom Infra Project's OpenBNG initiative 12/08/20 Casa Systems announces Software AG Cumulocity IoT partnership 09/09/20 Casa Systems unveils high-power 5G mmWave CPE CASA Casa Systems $8.03 / -0.47 (-5.53%) 02/19/21 Northland Casa Systems price target raised to $12 from $9 at Northland 01/14/21 Barclays Casa Systems upgraded to Overweight with $9 target at Barclays 01/14/21 Barclays Casa Systems upgraded to Overweight from Equal Weight at Barclays 04/14/20 JPMorgan Casa Systems initiated with an Underweight at JPMorgan CASA Casa Systems $8.03 / -0.47 (-5.53%) 02/18/21 Casa Systems sees FY21 EPS 23c-32c, consensus 31cc 02/18/21 Casa Systems reports Q4 EPS 27c, consensus 11c 02/18/21 Casa Systems reports Q4 EPS 27c, consensus 11c 10/28/20 Casa Systems raises FY20 EPS view to 9c-14c from 0c-12c, consensus 6c CASA Casa Systems $8.03 / -0.47 (-5.53%) 02/19/21 Fly Intel: Wall Street's top stories for Friday 02/19/21 Fly Intel: Wall Street's top stories at midday 02/18/21 Fly Intel: After-Hours Movers 10/28/20 Fly Intel: After-Hours Movers

Events

Earnings calls, analyst events, roadshows and more

ASIX
Tomorrow at 00:00

AdvanSix - ASIX Conference Calls
Tomorrow at 00:00

Asia Online Education Virtual Seminar Conferences

Virtual Seminar
Tomorrow at 00:00

42nd Annual Institutional Investors Virtual Conference Conferences

Virtual Conference
Tomorrow at 00:00

26th Annual Energy Virtual Summit Conferences

Virtual Summit
Tomorrow at 00:00

European Medtech & Services Virtual Conference Conferences

Virtual Conference
Tomorrow at 00:00

Paper & Packaging Virtual Summit Conferences

Virtual Summit
Tomorrow at 00:00

2021 London Global Healthcare Virtual Conference Conferences

Virtual Conference
Tomorrow at 00:00

Advances in Genome Biology & Technology: AGBT 2021 Virtual Event Conferences

Virtual Event
TMO ...
Tomorrow at 00:00

41st Annual Healthcare Virtual Conference Conferences

Virtual Conference
Tomorrow at 00:00

Global High Yield & Leveraged Finance Virtual Conference Conferences

Virtual Conference

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	SWTX X SWTX SpringsWorks Therapeutics Block Trade Managers: Morgan Stanley Priced at: $84.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRT X VRT Vertiv Holdings Block Trade Managers: JPMorgan Priced at: $20.70 17.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan Priced at: $120.00 2.08M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Secondary Managers: Goldman Sachs Priced at: $74.95 7M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $11.88 30M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan & Morgan Stanley Priced at: $166.50 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HLNE X HLNE Hamilton Lane Spot Secondary Managers: JPMorgan Priced at: $88.25 1.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JELD X JELD Jeld-Wen Spot Secondary Managers: Goldman Sachs Priced at: $29.25 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCL X RCL Royal Caribbean Spot Secondary Managers: Morgan Stanley Priced at: $91.00 16.938M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SITC X SITC Site Centers Spot Secondary Managers: Morgan Stanley & Wells Fargo Priced at: $13.20 15M Shares WSC X WSC WillScot Mobile Mini Spot Secondary Managers: Morgan Stanley Priced at: $27.20 12.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	RDHL X RDHL RedHill Biopharma Spot Secondary Managers: H.C. Wainwright $9.23 1.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	GROY X GROY Gold Royalty IPO Managers: H.C. Wainwright & BMO Capital, CIBC, HAYW, Raymond James, Roth Capital, Scotiabank, Sprott, TD Securities $5.00 16M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial OSCR X OSCR Oscar Health IPO Managers: Goldman Sachs, Morgan Stanley & Allen & Co., Wells Fargo, Credit Suisse, BofA, Cowen, LION, Ramirez, SIEB $36.00-38.00 31M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: Jefferies & Piper Sandler $5.25 Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDLX X CDLX Cardlytics Secondary Managers: BofA, JPMorgan, Wells Fargo & Raymond James $141.28 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HSKA X HSKA Heska Secondary Managers: JPMorgan & Piper Sandler $201.39 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INDT X INDT Indus Realty Trust Secondary Managers: Morgan Stanley, Citi & Baird, BTIG, JMP Securities, JPMorgan $62.68 1.75M Shares MORF X MORF Morphic Secondary Managers: Jefferies, Cowen, BMO Capital & RBC Capital $84.85 Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ICAD X ICAD iCAD Spot Secondary Managers: Guggenheim $18.00-18.25 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MGY X MGY Magnolia Oil & Gas Spot Secondary Managers: Credit Suisse & Citi $10.50-11.00 17M Shares ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan $5.55-5.65 8M Shares PLXP X PLXP PLx Pharma Spot Secondary Managers: Raymond James & Oppenheimer $9.14 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SSYS X SSYS Stratasys Spot Secondary Managers: JPMorgan & Stifel $29.00-30.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	INNV X INNV InnovAge IPO Managers: JPMorgan, Barclays, Goldman Sachs & Citi, Baird, William Blair, Piper Sandler, Capital One, Loop Capital, SIEB, Roberts & Ryans $17.00-19.00 16.667M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AMRK X AMRK A-Mark Precious Metals Secondary Managers: DA Davidson & Roth Capital, CIBC $27.97 2.5M Shares COHU X COHU Cohu Secondary Managers: Citi, Goldman Sachs & Stifel, B. Riley Securities, Craig-Hallum, DA Davidson $45.99 4.5M Shares DGII X DGII Digi International Secondary Managers: Piper Sandler $23.46 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FVRR X FVRR Fiverr Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley $279.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLQT X SLQT SelectQuote Secondary Managers: Credit Suisse, Morgan Stanley, Goldman Sachs, RBC Capital, Barclays, Citi, Evercore ISI & Jefferies, Cantor Fitzgerald, Keefe Bruyette, Piper Sandler, Drexel Hamilton $32.22 10.6M Shares
Thurs	NRIX X NRIX Nurix Therapeutics Secondary Managers: JPMorgan, Piper Sandler & Stifel, RBC Capital, Needham $35.91 4M Shares
Fri	No deals

View All Syndicate Announcements »

Revolution Medicines to present interim fata from Phase 1b/2 trial of RMC-4630

TODAY'S FREE FLY STORIES

Get Full Fly Access